Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer
Conditions
Circulating Tumor Cells
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Neoplastic Cells, Circulating
Conditions: Keywords
Non small-cell lung cancer, Circulating tumor cells, Carcinoembryonic antigen, Cytokeratin
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Overall Status
Recruiting
Summary
The purpose of the study is to evaluate the association between the number of circulating tumor cells and response to treatment in non small-cell lung cancer patients
Detailed Description
In spite of technological advantages in diagnosis and treatment, lung cancer remains one of the most deadly malignant neoplasias. Moreover, there are no markers for monitoring response to treatment. The objective of the study is to associate the number of circulating tumor cells (CTC) before and after treatment and correlate it with tumor response rate, progression-free survival and overall survival.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Histopathologic diagnosis of non small-cell lung cancer

- Clinical stage IV

- ECOG functional status 0 or 1

- No renal function alteration (GFR >50%)

- No hepatic function alteration (ALT and AST less than 2 times its normal value)

- Leucocytes more than 2,000/mcl

- Hemoglobin more than 10mg/dL

- Platelets more than 100,000/mcl

Exclusion Criteria:

Non-advanced disease
Location
National Institute of Cancerologia
Mexico City, Distrito Federal, Mexico
Status: Recruiting
Contact: Oscar Arrieta, MD - (0155)56280400 - ogar@servidor.unam.mx
Start Date
July 2007
Sponsors
National Institute of Cancerología
Source
National Institute of Cancerología
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page